Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …

Aims Left ventricular thrombus (LVT) increases the risk of thrombotic events and mortality.
Vitamin K antagonists (VKAs) used to treat LVT have several known risks, as a result of …

Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …

Background The extent to which the introduction of direct oral anticoagulants (DOACs)
influenced treatment patterns in frail and nonfrail patients with nonvalvular atrial fibrillation …

Acute ischemic stroke (AIS) is the most common type of stroke and requires immediate
reperfusion. Current acute reperfusion therapies comprise the administration of intravenous …

Over the past two decades, percutaneous left atrial appendage occlusion (LAAO) has
proven to be a viable alternative to oral anticoagulation (OAC) for stroke prevention in …

Introduction oral anticoagulant (DOAC) agents are becoming the anticoagulation strategy of
choice for most clinical risks for which they are indicated. However, residual uncertainty …

Background Little is known how individual time-in-therapeutic-range (TTR) impacts the
effectiveness and safety of warfarin therapy compared to direct oral anticoagulants (DOACs) …

Abstract Background Direct oral anticoagulants (DOACs) reduce stroke risk in patients with
device-detected atrial fibrillation (DD-AFib) but increase major bleeding risk. The time to …

ABSTRACT Background This Nordic observational cohort study aims to assess the
effectiveness and safety of reduced-dose direct-acting oral anticoagulants (DOACs) …